- World Pharma News Home » Product » Nexavar Study Demonstrates Significant Improvement in Overall Survival
(a free service delivered by FeedBurner)
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of Medicine published landmark results of a Nexavar study in liver cancer. The data of the Phase III trial showed that Nexavar® (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo. This represents a 44 percent improvement in median overall survival for patients treated with Nexavar. Based on the strength of these data, Nexavar was approved for HCC in the U.S. and Europe at the end of last year.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments